Artificial antigen presenting cells and uses thereof

Patent metadata

Field	Value
Publication number	US-9555105-B2
Application number	US-201414247298-A
Country	US
Kind code	B2
Filing date	Apr 8, 2014
Priority date	May 27, 2004
Publication date	Jan 31, 2017
Grant date	Jan 31, 2017

Abstract

The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of the invention can further comprise additional molecules useful for expanding a T cell of interest. The aAPC of the invention can be used as an “off the shelf” APC that can be readily designed to expand a T cell of interest. Also, the aAPC of the invention can be used identify the stimulatory, co-stimulatory, and any other factors that mediate growth and expansion of a T cell of interest. Thus, the present invention provides powerful tools for development of novel therapeutics where activation and expansion of a T cell can provide a benefit.

First claim

What is claimed is:

1. An isolated artificial antigen presenting cell (aAPC) comprising a K562 cell transduced with a lentiviral vector (LV), wherein said LV comprises a nucleic acid encoding at least one co-stimulatory ligand that specifically binds with at least one co-stimulatory molecule selected from the group consisting of CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, LFA-1, CD2, CD7, LIGHT, NKG2C, B7-H3, BTLA, Toll ligand receptor and a ligand that specifically binds with CD83, and said LV further comprises a nucleic acid encoding a CD64 molecule, and wherein said aAPC expresses said co-stimulatory ligand and said CD64 molecule loaded with anti-CD3 antibody, and further wherein said aAPC can stimulate and expand a T cell contacted with said aAPC.

2. The isolated aAPC of claim 1 , wherein said co-stimulatory ligand is at least one co-stimulatory ligand selected from the group consisting of CD7, B7-1 (CD80), B7-2 (CD86), PD-L1, PD-L2, 4-1BBL, OX40L, ICOS-L, ICAM, CD30L, CD40, CD70, CD83, HLA-G, MICA, MICB, HVEM, lymphotoxin beta receptor, ILT3, ILT4, 3/TR6, and a ligand that specifically binds with B7-H3.

3. The isolated aAPC of claim 1 , wherein said co-stimulatory ligand is an antibody that specifically binds with at least one molecule selected from the group consisting of CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, LFA-1, CD2, CD7, LIGHT, NKG2C, B7-H3, BTLA, Toll ligand receptor and a ligand that specifically binds with CD83.

4. The isolated aAPC of claim 1 , wherein said LV comprises a nucleic acid encoding at least one antigen selected from the group consisting of a tumor antigen, a viral antigen, a bacterial antigen, a peptide-MHC tetramer, a peptide-MHC trimer, a peptide-MHC dimer, and a peptide-MHC monomer.

5. The isolated aAPC of claim 4 , wherein said tumor antigen is selected from the group consisting of MAGE-1, MAGE-2, MAGE-3, MART-1, GP100, CEA, HER-2/Neu, PSA, WT-1, MUC-1, MUC-2, MUC-3, MUC-4, and telomerase.

6. The isolated aAPC of claim 1 , wherein said LV comprises a nucleic acid encoding at least one peptide selected from a cytokine and a chemokine.

7. The isolated aAPC of claim 6 , wherein said cytokine is at least one cytokine selected from the group consisting of IL-2, IL-4, IL-6, IL-7, IL-10, IL-12, IL-15, IL-21, interferon-alpha (IFNα), interferon-beta (IFNβ), interferon-gamma (IFNγ), tumor necrosis factor-alpha (TNFα), tumor necrosis factor-beta (TNFβ), granulocyte macrophage colony stimulating factor (GM-CSF), and granulocyte colony stimulating factor (GCSF).

8. The isolated aAPC of claim 6 , wherein said cytokine is at least one cytokine selected from the group consisting of IL-7, IL-15, and IL-21.

9. The isolated aAPC of claim 1 , wherein said nucleic acid encoding said CD64 molecule is SEQ ID NO:2.

Assignees

• Univ Pennsylvania

Inventors

• Riley James L
• June Carl H
• Vonderheide Robert H
• Aqui Nicole
• Davis Megan M

Classifications

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• G01N33/56972

  White blood cells · CPC title

• A61K39/12

  Viral antigens · CPC title

• A61K2035/124

  the cells being hematopoietic, bone marrow derived or blood cells · CPC title

• C12N2501/51

  B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand) · CPC title